Advertisement

PharmacoEconomics & Outcomes News

, Volume 828, Issue 1, pp 3–3 | Cite as

May 2019 news from ICER

News item
  • 4 Downloads

Evidence reports published

The US Institute for Clinical and Economic Review (ICER) has published Evidence Reports on the effectiveness and value of siponimod [Mayzent; Novartis] for the treatment of secondary progressive multiple sclerosis (SPMS)1, and on esketamine [Spravato; Janssen] for patients with treatment-resistant depression (TRD).2

Siponimod has been approved by the US FDA for the treatment of relapsing forms of multiple sclerosis including active SPMS. This report by ICER reviewed the clinical and cost-effectiveness of siponimod in patients with active and non-active SPMS (the study population in a phase III trial). "While the FDA did not approve siponimod for non-active SPMS, we felt it remained important to review the data assessing siponimod's potential benefit in all SPMS, including in those patients for whom disease mainly involves progression rather than relapses," said Dr David Rind, Chief Medical Officer at ICER. Economic analyses on the long-term cost effectiveness...

References

  1. 1.
    Institute for Clinical and Economic Review. ICER Publishes Evidence Report on the Use of Siponimod to Treat Secondary Progressive Multiple Sclerosis. Internet Document : 2 May 2019. Available from: URL: https://icer-review.org/announcements/spms_evidence_report/
  2. 2.
    ICER. ICER's Evidence Report Finds Esketamine May Benefit Patients with Treatment-Resistant Depression but Exceeds Cost-Effectiveness Thresholds. Internet Document : 9 May 2019. Available from: URL: https://icer-review.org/announcements/trd-evidence-report/
  3. 3.
    Institute for Clinical and Economic Review. ICER Posts Draft Scoping Document for the Assessment of Treatments for Type 2 Diabetes. Internet Document : 2 May 2019. Available from: URL: https://icer-review.org/announcements/diabetes2019_draft_scope/
  4. 4.
    Institute for Clinical and Economic Review. ICER Seeks Public Input for 2020 Value Assessment Framework. Internet Document : 2 May 2019. Available from: URL: https://icer-review.org/announcements/icer-seeks-public-input-for-2020-value-assessment-framework/

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations